Tag: signal

ROK Financial announces new loan pathways for pool and spa contractors heading into the 2025 season. By offering no credit check financing, fast approvals, and expanded loan ranges, the company addresses growing demand among small business owners with fair or poor credit histories. This initiative responds to the sharp rise in alternative lending searches and the increased pressure on contractors seeking reliable capital access as traditional banks tighten standards.

Demand for cannabis business financing in 2025 is reaching new levels as licensed operators search for reliable capital outside of traditional banks. ROK Financial has expanded access with no credit check loan options, addressing the growing need for small business funding solutions that work for owners with bad credit while staying aligned with state regulations and industry compliance.

Public curiosity around nerve health is rising in 2025, with searches, podcasts, and social platforms highlighting natural approaches. Nerve Soothe enters this conversation with a formula designed around ingredient transparency, plant-based extracts, and consumer-driven expectations for wellness support.

An In-Depth 2025 Analysis of PurelyWHITE Deluxe Teeth Whitening Powder and Consumer Trends in Sensitivity-Free Oral Care

Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No Warrants

Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market

Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.